Glaukos (NYSE:GKOS) Posts Earnings Results, Misses Expectations By $0.02 EPS

Glaukos (NYSE:GKOS) posted its quarterly earnings data on Thursday. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02), Zacks reports. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos updated its FY 2025 guidance to EPS.

Glaukos Trading Down 1.6 %

Shares of NYSE GKOS opened at $157.97 on Friday. The business has a 50 day simple moving average of $153.00 and a 200 day simple moving average of $139.16. Glaukos has a 52 week low of $83.90 and a 52 week high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Analyst Ratings Changes

A number of research firms have recently weighed in on GKOS. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research report on Monday, December 2nd. Truist Financial raised their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. BTIG Research lifted their price objective on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, Stifel Nicolaus boosted their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $159.42.

Insider Activity at Glaukos

In other news, COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. This trade represents a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.